Exegenesis Bio Announces a $20M Series B Financing Round

According to VCBeat, recently, Exegenesis Bio Inc. ("Exegenesis"), a company focused on gene therapy, has completed a US$20 million Series B financing led by Legend Capital, with participation from BioTrack Capital, TF Capital and the existing old shareholders including Xianfeng Qiyun Investment and Kaitai Capital. Haoyue Capital acted as the exclusive financial adviser for the deal. The funds raised will be used to promote the clinical researches and R&D of several pipelines in gene therapy of Exegenesis.

In October 2019, Exegenesis has raised over $10 million in its Series A funding round led by K2 Venture Partners with participation from Kaitai Capital and Legend Star.

Founded in July 2019, Exegenesis is a gene therapy company whose mission is to provide innovative and affordable treatment to patients with high unmet needs. Focusing on both the Chinese and the global market, Exegenesis aims to pioneer revolutionary new medicine through gene therapy research and development.

The founders of Exegenesis have over 15 years of experience in the cell and gene therapy field, and have served as executive positions in several well-known US gene therapy companies. The team's wide range of experience spans from gene therapy drug design, preclinical studies, and clinical development to GMP production.

In terms of mass production and the production process, Exegenesis takes a lead in the international market. It only takes 4 months to build a gene therapy production workshop conforming to the cGMP standard of China, the United States, and Europe. Its scalable and cost-controllable platform and mass production capacity can facilitate the development of multiple product lines of the company to be listed in the market.

Established in April 2001, Legend Capital is an independent professional Venture Capital firm under Legend Holdings. Legend Capital focuses on early-stage venture capital and expansion-stage growth capital investment. The company is now managing several USD funds and RMB funds with a total AUM of 45 billion yuan.

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. The company focuses on innovative biotech companies, innovative MedTech companies, and innovative business models in healthcare which are led by outstanding entrepreneurs.